Inhibitory effects of miR‑26b‑5p on thyroid cancer

Zhou,Aiya; Chen,Gengyu; Cheng,Xiankui; Zhang,Chi; Xu,Hao; Qi,Ming; Chen,Xiao; Wang,Tiantian; Li,Leping

doi:10.3892/mmr.2019.10315

Inhibitory effects of miR‑26b‑5p on thyroid cancer

Authors:
- Aiya Zhou
- Gengyu Chen
- Xiankui Cheng
- Chi Zhang
- Hao Xu
- Ming Qi
- Xiao Chen
- Tiantian Wang
- Leping Li
View Affiliations

Affiliations: Department of Traditional Chinese Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250101, P.R. China, The Second Department of General Surgery, The Fourth Hospital of Jinan City, Jinan, Shandong 250021, P.R. China, Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250101, P.R. China, Department of General Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250101, P.R. China
Published online on: May 31, 2019 https://doi.org/10.3892/mmr.2019.10315
Pages: 1196-1202
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In order to examine the inhibitory effects of microRNA (miR)‑26b‑5p on thyroid cancer (TC), the clinicopathological features and pathological tissues of 67 patients were collected. The expression levels of miR‑26b‑5p were detected in TC and paracarcinoma tissues by quantitative polymerase chain reaction, and the association between miR‑26b‑5p expression and the clinicopathological features of the patients was analyzed using t‑test or one‑way analysis of variance. In addition, B‑CPAP TC cells were infected with a lentivirus to induce miR‑26b‑5p overexpression and proliferation was detected by Cell Counting kit‑8. Subsequently, migration and invasion were detected by Transwell and Matrigel assays, respectively, and the molecular mechanism of action was investigated by western blotting. The results demonstrated that the expression levels of miR‑26b‑5p were significantly lower in TC tissues compared with paracarcinoma tissues (P<0.01), and miR‑26b‑5p was associated with lymph node metastasis (P<0.05). In addition, overexpression of miR‑26b‑5p inhibited the proliferation, invasion and migration of B‑CPAP cells. Western blot analysis demonstrated that the protein expression levels of phosphorylated glycogen synthase kinase‑3β (pGsk‑3β) were decreased, and the expression of β‑catenin was decreased in B‑CPAP cells overexpressing miR‑26b‑5p. These results demonstrated that miR‑26b‑5p may exert antitumor activity. In addition, at the molecular level, these effects may be associated with the Gsk‑3β/β‑catenin pathway.

View Figures

View References

1	Randle RW, Bushman NM, Orne J, Balentine CJ, Wendt E, Saucke M, Pitt SC, Macdonald CL, Connor NP and Sippel RS: Papillary thyroid cancer: The good and bad of the ‘Good Cancer’. Thyroid. 27:902–907. 2017. View Article : Google Scholar : PubMed/NCBI
2	Garau LM, Rubello D, Ferretti A, Boni G, Volterrani D and Manca G: Sentinel lymph node biopsy in small papillary thyroid cancer. A review on novel surgical techniques. Endocrine. 62:340–350. 2018. View Article : Google Scholar : PubMed/NCBI
3	Yan S, Zhao W, Wang B and Zhang L: Preoperative injection of carbon nanoparticles is beneficial to the patients with thyroid papillary carcinoma: From a prospective study of 102 cases. Medicine (Baltimore). 97:e113642018. View Article : Google Scholar : PubMed/NCBI
4	Paulsson JO, Zedenius J and Juhlin CC: Papillary thyroid carcinoma with pleomorphic tumor giant cells in a pregnant woman-a case report. BMC Endocr Disord. 18:462018. View Article : Google Scholar : PubMed/NCBI
5	Yongfu Z, Ziyu L, Chen L and Jingchao X: Cervical mass as the initial manifestation of occult papillary thyroid carcinoma: Report of three cases. J Cancer Res Ther. 14 (Suppl):S544–S548. 2018. View Article : Google Scholar : PubMed/NCBI
6	Hardin H, Helein H, Meyer K, Robertson S, Zhang R, Zhong W and Lloyd R: Thyroid cancer stem-like cell exosomes: Regulation of EMT via transfer of lncRNAs. Lab Invest. 98:1133–1142. 2018. View Article : Google Scholar : PubMed/NCBI
7	Ma B, Wei W, Xu W, Wang Y, Guan H, Fan J, Zhao Z, Wen D, Yang S, Wang Y, et al: Surgical confirmation of incomplete treatment for primary papillary thyroid carcinoma by percutaneous thermal ablation: A retrospective case review and literature review. Thyroid. 28:1134–1142. 2018. View Article : Google Scholar : PubMed/NCBI
8	Henn D, Abu-Halima M, Falkner F, Wermke D, Meme LG, Kühner C, Keller A, Kneser U, Meese E, Schmidt V, et al: Micro-RNA regulated pro-angiogenic signaling in arteriovenous loops in patients with combined vascular and soft tissue reconstructions-reisiting the nutrient flap concept. Plast. Reconstr. Surg. 142:12018.
9	Gomes A, da Silva IV, Rodrigues CMP, Castro RE and Soveral G: The emerging role of microRNAs in aquaporin regulation. Front Chem. 6:2382018. View Article : Google Scholar : PubMed/NCBI
10	Nigita G, Distefano R, Veneziano D, Romano G, Rahman M, Wang K, Pass H, Croce CM, Acunzo M and Nana-Sinkam P: Tissue and exosomal miRNA editing in non-small cell lung cancer. Sci Rep. 8:102222018. View Article : Google Scholar : PubMed/NCBI
11	Uen Y, Wang J, Wang C, Jhang Y, Chung J, Tseng T, Sheu M and Lee S: Mining of potential microRNAs with clinical correlation-regulation of syndecan-1 expression by miR-122-5p altered mobility of breast cancer cells and possible correlation with liver injury. Oncotarget. 9:28165–28175. 2018. View Article : Google Scholar : PubMed/NCBI
12	Liu DT, Yao HR, Li YY, Song YY and Su MY: MicroRNA-19b promotes the migration and invasion of ovarian cancer cells by inhibiting the PTEN/AKT signaling pathway. Oncol Lett. 16:559–565. 2018.PubMed/NCBI
13	Hersi HM, Raulf N, Gaken J, Folarin N and Tavassoli M: MicroRNA-9 inhibits growth and invasion of head and neck cancer cells and is a predictive biomarker of response to plerixafor, an inhibitor of its target CXCR4. Mol Oncol. 12:2023–2041. 2018. View Article : Google Scholar : PubMed/NCBI
14	Liu X, He M, Hou Y, Liang B, Zhao L, Ma S, Yu Y and Liu X: Expression profiles of microRNAs and their target genes in papillary thyroid carcinoma. Oncol Rep. 29:1415–1420. 2013. View Article : Google Scholar : PubMed/NCBI
15	Yang Z, Yuan Z, Fan Y, Deng X and Zheng Q: Integrated analyses of microRNA and mRNA expression profiles in aggressive papillary thyroid carcinoma. Mol Med Rep. 8:1353–1358. 2013. View Article : Google Scholar : PubMed/NCBI
16	Wu T, Chen W, Liu S, Lu H, Wang H, Kong D, Huang X, Kong Q, Ning Y and Lu Z: Huaier suppresses proliferation and induces apoptosis in human pulmonary cancer cells via upregulation of miR-26b-5p. FEBS Lett. 588:2107–2114. 2014. View Article : Google Scholar : PubMed/NCBI
17	Mei JY, Zhang MJ, Wang YY and Liu YH: The positive clinical therapeutically effects of Escin on advanced thyroid cancer. Cancer Med. 6:937–943. 2017. View Article : Google Scholar : PubMed/NCBI
18	Abbosh PH and Nephew KP: Multiple signaling pathways converge on beta-catenin in thyroid cancer. Thyroid. 15:551–561. 2005. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Wakasa T, Li Y, Bai Y, Liu Z, Ozaki T, Mori I, Miyauchi A, Kakudo K and Nakamura M: Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism. Pathol Res Pract. 210:733–738. 2014. View Article : Google Scholar : PubMed/NCBI
21	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manualand the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
22	Ambros V: MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing. Cell. 113:673–676. 2003. View Article : Google Scholar : PubMed/NCBI
23	Farazi TA, Hoell JI, Morozov P and Tuschl T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013. View Article : Google Scholar : PubMed/NCBI
24	Menon MP and Khan A: Micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications. J Clin Pathol. 62:978–985. 2009. View Article : Google Scholar : PubMed/NCBI
25	Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM and Fusco A: MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 14:791–798. 2007. View Article : Google Scholar : PubMed/NCBI
26	Sui GQ, Fei D, Guo F, Zhen X, Luo Q, Yin S and Wang H: MicroRNA-338-3p inhibits thyroid cancer progression through targeting AKT3. Am J Cancer Res. 7:1177–1178. 2017.PubMed/NCBI
27	Lima CR, Geraldo MV, Fuziwara CS, Kimura ET and Santos MF: miRNA-146b-5p upregulates migration and invasion of different Papillary Thyroid Carcinoma cells. BMC Cancer. 16:1082016. View Article : Google Scholar : PubMed/NCBI
28	Liu J, Li Q, Li R, Ren P and Dong S: MicroRNA-363-3p inhibits papillary thyroid carcinoma progression by targeting PIK3CA. Am J Cancer Res. 7:148–158. 2017.PubMed/NCBI
29	Zhang X, Li D, Li M, Ye M, Ding L, Cai H, Fu D and Lv Z: MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development. Int J Cancer. 134:257–267. 2014. View Article : Google Scholar : PubMed/NCBI
30	Yin Y, Hong S, Yu S, Huang Y, Chen S, Liu Y, Zhang Q, Li Y and Xiao H: miR-195 inhibits tumor growth and metastasis in papillary thyroid carcinoma cell lines by targeting CCND1 and FGF2. Int J Endocrinol. 2017:61804252017. View Article : Google Scholar : PubMed/NCBI
31	Cheng L, Zhou R, Chen M, Feng L and Li H: MicroRNA-150 targets Rho-associated protein kinase 1 to inhibit cell proliferation, migration and invasion in papillary thyroid carcinoma. Mol Med Rep. 16:2217–2224. 2017. View Article : Google Scholar : PubMed/NCBI
32	Kato M, Goto Y, Matsushita R, Kurozumi A, Fukumoto I, Nishikawa R, Sakamoto S, Enokida H, Nakagawa M, Ichikawa T and Seki N: MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer. Int J Oncol. 47:710–718. 2015. View Article : Google Scholar : PubMed/NCBI
33	Kozubek J, Ma Z, Fleming E, Duggan T, Wu R, Shin DG and Dadras SS: In-depth characterization of microRNA transcriptome in melanoma. PLoS One. 8:e726992013. View Article : Google Scholar : PubMed/NCBI
34	Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S and Kikuchi A: Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J. 17:1371–1384. 1998. View Article : Google Scholar : PubMed/NCBI
35	Forde JE and Dale TC: Glycogen synthase kinase 3: A key regulator of cellular fate. Cell Mol Life Sci. 64:1930–1944. 2007. View Article : Google Scholar : PubMed/NCBI
36	Farago M, Dominguez I, Landesman-Bollag E, Xu X, Rosner A, Cardiff RD and Seldin DC: Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res. 65:5792–5801. 2005. View Article : Google Scholar : PubMed/NCBI
37	Jiang Y, Miao J, Wang D, Zhou J, Liu B, Jiao F, Liang J, Wang Y, Fan C and Zhang Q: MAP30 promotes apoptosis of U251 and U87 cells by suppressing the LGR5 and Wnt/β-catenin signaling pathway, and enhancing Smac expression. Oncol Lett. 15:5833–5840. 2018.PubMed/NCBI
38	Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
39	Chen XJ, Meng J, Yue W, Yu J, Yang J, Yao Z and Zhang L: Fibulin-3 suppresses Wnt/β-catenin signaling and lung cancer invasion. Carcinogenesis. 35:1707–1716. 2014. View Article : Google Scholar : PubMed/NCBI
40	Aman A and Piotrowski T: Wnt/beta-catenin and Fgf signaling control collective cell migration by restricting chemokine receptor expression. Dev Cell. 15:749–761. 2008. View Article : Google Scholar : PubMed/NCBI
41	Lv M, Zhang X, Li M, Chen Q, Ye M, Liang W, Ding L, Cai H, Fu D and Lv Z: miR-26a and its target CKS2 modulate cell growth and tumorigenesis of papillary thyroid carcinoma. PLoS One. 8:e675912013. View Article : Google Scholar : PubMed/NCBI
42	Lin L, Fang Z, Lin H, Lin H, You H, Wang J, SU H, Wang F and Zhang ZY: Depletion of Cks1 and Cks2 expression compromises cell proliferation and enhance chemotherapy-induced apoptosis in HepG2 cells. Oncol Rep. 35:26–32. 2016. View Article : Google Scholar : PubMed/NCBI